Is a whole-body MRI scan (Prenuvo, Neko Health) worth it for a healthy person?

Short version: if you are an asymptomatic adult at average risk, there is no good evidence this scan helps you live longer. Not because a big trial tested it and came up empty. Because no randomized trial has ever tested whether whole-body MRI screening reduces death from cancer or any cause. The headline benefit rests on absence of evidence, not on a proven null result. That is a very different thing.

Look at how thin the foundation is. Kwee and Kwee 2019 pulled together 12 studies covering 5,373 asymptomatic people. Not one of those studies verified what happened to negative findings over the long term. Dai and Kang 2026 go further and call asymptomatic multi-disease MRI a major divergence from conventional screening principles, with benefits unsupported by population-level data.

Meanwhile the marketing wave is arriving. Prenuvo (US) opened its first European clinic in London in 2025. Neko Health, the Swedish company co-founded by Spotify's Daniel Ek, is pushing in too, but its product is not an MRI at all: a sensor-based body scan plus blood markers, priced far lower (around £299 in London). Slick branding, calm clinics, the promise of catching cancer before it catches you.

Here is the catch. The actual yield is tiny. Pooled cancer detection in asymptomatic people sits at about 1.57% (Martins da Fonseca et al. 2025, 10 studies, 9,024 people). That modest signal gets buried under everything else the scan turns up.

So the trade is simple to state, hard to swallow. You buy a small chance of finding a real cancer. You buy a near-certain pile of incidental findings alongside it. A normal scan does not rule out fast-growing tumors or cancers in hollow organs. An abnormal scan is far more likely to start a workup than to save your life. This is not a clean peace-of-mind purchase, whatever the website says.

MRI is genuinely good at some things. It images soft tissue beautifully and uses no radiation at all. It can spot certain solid-organ tumors and lesions in the kidney or liver, aneurysms (a ballooning weak spot in a blood vessel wall), and various masses. If a tumor is a solid lump sitting in an organ MRI can scan well, the scan can see it.

Notice the gap, though. Seeing something is not the same as finding a lethal cancer early enough to change your outcome.

Now the blind spots, and they are the ones that break the screening promise. Early lung cancer? Poorly captured. Early colon and colorectal cancer? Poorly captured. Most disease in hollow organs (the lung, the bowel, the bladder, anything with air or an open cavity) slips past a whole-body MRI. These are exactly the cancers that kill at population scale.

That is precisely why the scan cannot replace the screening that actually has evidence behind it: mammography, colonoscopy, and Pap or HPV testing. Professional reviews treat whole-body MRI as a divergence from established screening, not an upgrade to it (Dai and Kang 2026; ACR 2023).

On safety, give MRI its due. Compared with a CT scan or a coronary calcium (CAC) scan, which use ionizing radiation, MRI carries no radiation dose. That advantage is real. But the dominant harm here was never radiation. It is the cascade of findings the scan sets off, which the next section covers.

So where does this land? Treat whole-body MRI as additive imaging that overlaps poorly with the cancers most likely to kill you. A normal result can hand you false reassurance about lung and bowel cancer specifically, the two areas where MRI is weakest. A clean scan is not a clean bill of health, and it does not cancel the age-appropriate screening you already qualify for.

Almost everyone lights up. About 95% of asymptomatic scans show at least one abnormal finding, and roughly 91% of those findings are clinically irrelevant (Dai and Kang 2026). Read that twice. Out of every 20 people scanned, 19 get told about something. For almost all of them, that something means nothing.

Keep the numbers honest and separate, though. The 95% and 91% figures cover any finding and irrelevant findings. The share that actually warrants attention is smaller: Kwee and Kwee 2019 pooled the critical-plus-indeterminate rate at about 32% (95% CI 18 to 50%). Do not conflate the two. About a third of scans surface something a radiologist flags as needing a second look.

How many of those flags turn out to be real? Here the data get leaky. The pooled false-positive proportion was about 16% (95% CI 1.9 to 65.8%), and only about 12.6% of critical or indeterminate findings were ever verified (Kwee and Kwee 2019). Those enormous confidence intervals are not a footnote. They are the story: the underlying evidence is weak and wildly inconsistent. Gibson et al. 2018 (BMJ) and the O'Sullivan et al. 2018 umbrella review corroborate how common incidental findings are across body imaging.

Now the concrete DACH harm. In the German SHIP population cohort (Richter et al. 2020), 3,371 people were scanned. 30.3% had incidental findings disclosed, most tumor-related. Of the biopsies that followed, 62.1% found no malignancy or tumor at all. That is overdiagnosis made flesh: real needles, real tissue removed, mostly chasing benign lesions.

So, the honest now-what. One finding triggers more MRIs, blood tests, specialist appointments, and sometimes biopsies that carry their own complication risk. Most of that chases something harmless. The cost, the lost time, and the anxiety are not rare side effects. They are the near-certain price of admission.

The consensus is plain: major professional bodies do not endorse whole-body MRI screening for average-risk, asymptomatic people. The American College of Radiology says it directly. Its 2023 Statement on Screening Total Body MRI finds insufficient evidence to recommend total-body screening in people without risk factors or family history, and says it should not be offered for preventive screening outside research. The Royal Australian and New Zealand College of Radiologists put out a 2024 position statement on whole-body MRI screening in low-risk patients that formalises the same stance.

This is not gatekeeping for its own sake. The reasoning is the harm profile you have already seen: false positives, incidentalomas, overdiagnosis, and no demonstrated mortality benefit. Those are exactly why the bodies hold back (Zugni et al. 2020; Dai and Kang 2026 on divergence from screening principles). A test that flags one in three people, verifies almost none of it, and has never been shown to save a life is a hard thing to recommend in good conscience.

One caveat worth keeping honest, because skeptics should cut both ways. The psychological-harm evidence is mixed, not damning. Conti et al. 2025 followed 121 asymptomatic people, all of whom had abnormal findings, and reported only a slight short-term mood change with no clear long-term psychosocial harm. But the longitudinal sample shrank to 61, so treat that as weak evidence either way. It is neither strong reassurance nor proof of lasting damage. Telling someone they have an abnormal finding is not automatically traumatic; it is also not free.

A DACH note, kept honest. A clean primary position statement from the Deutsche Roentgengesellschaft (DRG) on self-pay whole-body MRI screening was not located for this guide. So the consensus here rests on the ACR (2023) and RANZCR (2024). There is no fabricated German-society quote, because we could not verify one.

There is one legitimate niche, and it is narrow: people with high-risk hereditary cancer syndromes. The clearest case is Li-Fraumeni syndrome, caused by an inherited fault in the TP53 gene, which drives a very high lifetime cancer risk. For these carriers, whole-body MRI surveillance has real evidence behind it.

The numbers shift dramatically. Dacoregio et al. 2024 pooled 11 studies covering 703 TP53 carriers: baseline MRI confirmed cancer in about 18% of suspicious lesions, with early-stage cancer detection around 6%, and 41 of 46 cancers caught at an early stage. Temperley et al. 2024 (506 carriers) found a pooled cancer-detection proportion of about 7%, with Ballinger et al. 2017 (JAMA Oncology) corroborating. Compare that to 1.57% in average-risk people. The same scan, four to seven times more useful.

Why does the niche logic hold? Pre-test probability, not magic. In a population where cancer is genuinely common, the same test flips from mostly false alarms to genuine early catches. That is also why the anecdote does not transfer. Someone telling you the scan found their cousin's tumor may be true, but it does not generalise to a healthy average-risk buyer. The cousin's odds were never your odds.

So who should skip it? Asymptomatic, average-risk adults with no qualifying hereditary syndrome. That is exactly who the marketing targets, and exactly who has the weakest case. And if you have actual symptoms (a lump, persistent pain, bleeding), you do not need a screening scan. You need a targeted diagnostic work-up through a doctor, which is a different and faster path.

One more framing. If you carry a known high-risk germline mutation, surveillance is a medical decision made with a genetics or oncology team, often covered as care. It is not a consumer self-pay scan you book online between a sauna session and a smoothie.

In the DACH region, whole-body MRI screening is a self-pay service. In Germany it is an IGeL (Individuelle Gesundheitsleistung), and it runs roughly 1,500 to 3,000 EUR per scan (Prenuvo's London clinic lists about £2,499). Statutory insurance (GKV) does not cover it for average-risk screening. Neko Health's body-scan-plus-blood model is structured and priced differently, generally cheaper than a standalone Prenuvo-style MRI. Read the non-coverage as a signal, not a loophole: GKV declining to pay mirrors the guideline stance that this is not evidence-based screening.

The sticker price is the smaller bill. The real spend starts when an incidental finding sets off follow-up imaging, specialist visits, and biopsies, much of it out of pocket too. Tie it back to Richter et al. 2020: 62.1% of biopsies in that German cohort found nothing malignant, yet each one carried cost, time, and its own complication risk. The scan price quietly understates the total.

Then there is your data, and this part deserves real attention. A whole-body image of you is sensitive health data. Add blood markers and AI analysis, as Neko does, and the stakes climb. Worth asking honestly: where do the scans and the AI processing actually happen, US servers or EU servers, for Prenuvo and Neko? What exactly are you consenting to? How long is your imaging retained, and who can access it? Under GDPR these are not idle questions. The efficacy literature does not settle them, so treat them as questions to put to the provider before you book, not a verdict.

Honest bottom line for a self-pay buyer. If you are an average-risk healthy adult, the money does more for you elsewhere. Finish the guideline screening you actually qualify for: mammography, colonoscopy, cervical screening, plus evidence-based blood markers. Reserve whole-body MRI for the hereditary-syndrome niche or a research setting. That is where the scan earns its keep, and where it does not.